1. Global Projections for Diabetes: 2003-2025

2. Efficacy of DPP-4 Inhibitor Therapy Added to Metformin

3. DPP-4 Inhibitors vs SUs Added to Metformin: 2-Year Results

4. Glycemic Control With GLP-1 RAs: Head-to-Head Studies

5. Efficacy and Safety: SGLT2 Inhibitor vs Sitagliptin (DPP-4 Inhibitor) Added to Metformin

6. SGLT2 Inhibitor vs SU Added to Metformin

7. Effect of Liraglutide Dose on Mean Weight Change Response

8. SGLT2 Inhibitor Pooled Data: Weight Reduction in Placebo-Controlled Studies

9. SGLT2 Inhibitor: Weight Loss Is Mostly Fat

10. DPP-4 Inhibitor vs SGLT2 Inhibitor: Effect on SBP in T2DM

11. SAVOR-TIMI 53: Primary Endpoint

12. SAVOR-TIMI 53: Hospitalization for HF

13. EXAMINE: Primary Endpoint

14. EXAMINE: Hospitalization for HF

15. TECOS: Effect of Sitagliptin vs Placebo on CV Outcomes in T2DM

16. TECOS: Hospitalization for HF

19. EMPA-REG OUTCOME: Effect of Empagliflozin vs Placebo on the Primary Composite Outcome

20. EMPA-REG OUTCOME: Effect of Empagliflozin vs Placebo on CV Death

21. EMPA-REG OUTCOME: Effect of Empagliflozin vs Placebo on All-Cause Mortality

22. EMPA-REG OUTCOME: Effect of Empagliflozin vs Placebo on HF Hospitalization

23. DUAL-I: HbA1c Comparison

24. DUAL-I: Percentage of Patients to Target HbA1c

25. DUAL-I: Change in Body Weight

26. DUAL-I: Confirmed Hypoglycemia

27. DUAL-I: Nausea Over 26 Weeks